The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ATYR | -71.16% | -70.81% | -21.83% | -100% |
| S&P | +14.5% | +93.32% | +14.09% | +217% |
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
The next couple of weeks could reveal a great deal about this stock's prospects.
Clinical trial results expected in the weeks ahead could push shares of these small-cap drugmakers through the roof.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.39M | -1.0% |
| Gross Margin | -227.66% | 0.0% |
| Market Cap | $451.25M | 319.2% |
| Market Cap / Employee | $7.65M | 0.0% |
| Employees | 59 | 0.0% |
| Net Income | -$19.53M | -19.8% |
| EBITDA | -$19.93M | -17.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $17.22M | 153.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $11.35M | -10.5% |
| Short Term Debt | $1.33M | 13.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -64.24% | -15.7% |
| Return On Invested Capital | -52.28% | 4.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$13.90M | 32.0% |
| Operating Free Cash Flow | -$13.89M | 32.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.04 | 4.20 | 3.62 | 6.01 | 376.28% |
| Price to Sales | 219.14 | 191.77 | 567.71 | 1274.31 | 438.35% |
| Price to Tangible Book Value | 2.04 | 4.20 | 3.62 | 6.01 | 376.28% |
| Enterprise Value to EBITDA | -4.55 | -15.37 | -12.84 | -19.52 | 589.48% |
| Return on Equity | -78.0% | -79.7% | -79.5% | -85.2% | 38.19% |
| Total Debt | $13.57M | $13.28M | $12.99M | $12.68M | -8.47% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
